
Novartis

H. Lundbeck A/S

Acorda Therapeutics

BioEclipse Therapeutics

Jaguar Health

Amicus Therapeutics

CARsgen Therapeutics

MSD, Montes Claros, MG, Brazil

Flagship Pioneering

Elevation Oncology

Janssen Supply Chain

Warburg Pincus

Nkarta Therapeutics

Scorpion Therapeutics

Life Science Leader

Ferring Pharmaceutical, Inc.

Acrivon Therapeutics

PureTech Health

Merck

Context Therapeutics

Sangamo Therapeutics

Euclidean Life Science Advisors, LLC

Mythic Therapeutics

Aisling Capital

Alnylam Pharmaceuticals

X4 Pharmaceuticals

Danaher Corporation

MichBio

Alexion

Life Science Leader

Auven Therapeutics

ImmuneID

Radius Health


Voyager Therapeutics

MedImmune / AstraZeneca

Alexion

Dermira


MiMedx
ASK THE BOARD
- What New Value-Based Contracting Models For Cell And Gene Therapies Will Be Needed To Promote Broad Patient Access?
- Ongoing Economic Uncertainty And The Exit Of Generalist Investors From Biopharmaceuticals Continue To Put Pressure On Biopharma Company Leaders. What Advice Would You Offer?
- What Tips Would You Give To An Early-Stage Biopharma CEO Preparing To Present New Clinical Data At A Medical Meeting?
- Do You Think That Biopharmaceutical Companies Receiving An FDA Accelerated Approval Should Be Required To Enroll Patients In A Confirmatory Study Prior To Launch?
- What Key Characteristics Or Attributes — Beyond Functional Or Scientific Expertise — Should A CEO Look For In Considering The Addition Of A New Board Member?
- What Advice Would You Give To Small Biotechs That Have Delayed Or Canceled Plans For A Public Offering, But Still Need Funding To Advance Clinical Programs?
IN THIS MONTH'S ISSUE
@LIFESCILEADER1
This website uses cookies to ensure you get the best experience on our website. Learn more